PSORIASIS

CHRONIC, NON-COMMUNICABLE DISEASE OF THE IMMUNE SYSTEM

125 MILLION PEOPLE ARE AFFECTED WORLDWIDE

Please visit www.ifpma.org for more information.

PHYSICAL SYMPTOMS

Up to 90% of patients suffer from symptoms which can be painful, disfiguring and disabling.

Thick, red skin

Scaling

Itching

Pain

PSYCHOLOGICAL IMPACT

The psychosocial impact of psoriasis can be devastating, and patients suffer from isolation and depression due to stigmatization.

44% increased risk of suicidal thoughts, suicide attempts or completed suicides in patients compared to the general population.

90% of patients feel stigmatized.

52% of patients report significant psychiatric symptoms.

60% of patients consider psoriasis to have a major effect on their quality of life.

91% of patients report lower self-confidence from their disease.

CO-MORBIDITIES

Psoriasis is associated with numerous serious, debilitating and sometimes chronic comorbidities.

30% of patients are diagnosed with Psoriatic arthritis.

Patients have an increased risk for type 2 diabetes, and those with severe psoriasis were 46 percent more likely to have type 2 diabetes.

People with severe psoriasis are 58 percent more likely to have a major cardiac event and 43 percent more likely to have a stroke.

Approximately 25% of patients report psychological comorbidities such as stress, anxiety and depression.

SOCIO-ECONOMIC IMPACT

The life expectancy of patients is approximately 10 years lower than the general population.

Total annual cost of psoriasis in the USA was estimated to be $11.25 billion.

Lost productivity costs (leaving work earlier than usual, absence due to illness and loss of leisure time) have been found to account for 22-43% of the mean annual cost of psoriasis.

One in four people experience that it is harder to get work if you have psoriasis.

Patients would choose an approximately 50% lower life expectancy to be free of the disease for the rest of their lives.

TREATMENTS

Although there is no cure for psoriasis, it is treatable.

Many different therapies are available that reduce symptoms, restore patients’ self-confidence and improve quality of life.

There is still a need for new innovative medicines for the treatment of psoriasis.

TOPICAL THERAPY

- Fixed combination of betamethasone dipropionate and calcipotriol
- Vitamin D3 analogues
- Steroids
- Retinoids
- Dithranol

PHOTOTHERAPY (plus retinoids)

- PUVA (Systemic, local)
- UVB (311 nm)
- UVA/UVB

SYSTEMIC THERAPY

- Biologicals
- Methotrexate
- Fumaric acid esters

Mild Psoriasis

- 52% of patients

Moderate Psoriasis

- 36% of patients

Severe Psoriasis

- 12% of patients